BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.

Slides:



Advertisements
Similar presentations
High rates of survival, virologic suppression and immune reconstitution among patients receiving second-line ART in the Indian national programme B.B.
Advertisements

IAS–USA Managing Antiretroviral Failure in 2012 Jennifer Hoy, MD Professor of Medicine Director, HIV Medicine The Alfred Hospital FINAL: Presented.
HIV in the United Kingdom: 2013 HIV and AIDS Reporting Section Centre for Infectious Disease Surveillance and Control (CIDSC) Public Health England London,
Switch to EVG/c/FTC/TDF  STRATEGY-PI Study  STRATEGY-NNRTI Study.
Changing Therapy Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents published October 2006 AETC NRC Slide Set.
Feedback from Pregnancy research group UK CHIC / UK HIV Drug Resistance Database Meeting, 2 July 2010 Pregnancy Group: Jane Anderson, Loveleen Bansi, Susie.
Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels. Viradapt.
Inputs to a case-based HIV surveillance system. Objectives  Review HIV case definitions  Understand clinical and immunologic staging  Identify the.
Validating five questions of antiretroviral non-adherence in a decentralized public-sector antiretroviral treatment program in rural South Africa Krisda.
DRAFT BHIVA GUIDELINES Routine monitoring of HIV UK-CAB 31 July 2009 Matt Williams writing committee community rep.
1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Future ART options for HIV-infected children exposed to maternal HAART Lee Kleynhans Experts Roundtable June 2008.
Background There is uncertainty regarding the frequency, predictors, and outcomes of IRIS events Prior studies on IRIS have been limited to convenience.
THE NEVEREST STUDY AT RAHIMA MOOSA MCH Ashraf Coovadia Adjunct Professor Enhancing Childhood HIV Outcomes (Wits Paediatric HIV Clinics) Rahima Moosa Mother.
BHIVA national clinical audit of ART Dr Margaret Johnson, Chair of BHIVA clinical audit committee Dr Gary Brook Vice-Chair of BHIVA clinical audit committee.
Antiretroviral Postexposure Prophylaxis after Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV in the United States Recommendations.
Older and wiser: continued improvements in clinical outcome and highly active antiretroviral therapy (HAART) response in HIV-infected children in the UK.
2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents Summary of WHO Rapid Advice December 2009 Source: WHO HIV/AIDS Department.
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.
Switch to ATV/r + 3TC  SALT Study. ATV/r 300/100 mg qd + 2 NRTI (investigator-selected) N = 143 ATV/r 300/100 mg + 3TC 300 mg qd  Design Randomisation*
When to Initiate ART in Adults and Adolescents (2009 WHO Guidelines) Target PopulationClinical conditionRecommendation Asymptomatic Individuals (including.
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection DR. S.K CHATURVEDI DR. KANUPRIYA CHATURVEDI.
Catherine Kober Margaret Johnson Martin Fisher Caroline Sabin On behalf of UK-CHIC BHIVA/BASHH Manchester 2010 Non-uptake of HAART among patients with.
BHIVA Audit Survey of patient assessment and monitoring Set-up phase of cohort audit of patients starting ART from naïve.
TB/HIV management survey  Baseline audit in parallel with guidelines development process  Survey of clinician opinion and practice  Data collection.
EARLY CHILDHOOD OUTCOMES AT THE BOTSWANA- BAYLOR CHILDREN’S CLINICAL CENTRE OF EXCELLENCE: A REPORT TO THE WHO TECHNICAL REFERENCE GROUP ON PEDIATRIC CARE.
ZIMBABWE AIDS CARE FOUNDATION NEWLANDS CLINIC Virological Outcomes in Adult Patients on Second Line ART, at Newlands Clinic Dr S. Bote.
The Pregnancy Journey Open discussion. HIV and AIDS 2013 Romania Cumulative number people diagnosed with HIV since ,261 (of which 9,946 diagnosed.
Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.
Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.
Comparison of NNRTI vs PI/r  EFV vs LPV/r vs EFV + LPV/r –A5142 –Mexican Study  NVP vs ATV/r –ARTEN  EFV vs ATV/r –A5202.
ANTEPARTUM CARE. Pregnant Women Who Are ARV Naive (1)  Pregnant women with HIV infection should receive standard clinical, immunologic, and virologic.
Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.
INTRODUCTION A previous cohort study from our unit suggested a benefit for the use of efavirenz compared to nevirapine in a group of patients initiating.
Long Term Therapeutic Success of Etravirine in Switch and Naive Patients L.Bull, M.Bower, M.Nelson Chelsea and Westminster Hospital, London.
Audit of outcomes in HIV BHIVA Audit and Standards Sub-Committee E Ong (chair), J Anderson, D Churchill, M Desai, S Edwards, S Ellis, A Freedman, P Gupta,
1 Adherence to ARV Therapy and Resistance HAIVN Havard Medical School AIDS Initiative in Vietnam.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Human Immune Deficiency Virus Infection Dr Huda Taha Sep 2015.
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Major Changes to the HHS Adult and Adolescent HIV Treatment Guidelines: April 2015 Brian R. Wood, MD.
Response to Antiretroviral Treatment In an Ethiopian Hospital Samuel Hailemariam, MD, MPH; J Allen McCutchan, MD, MSc Meaza Demissie, MD, PMH, PHD; Alemayehu.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
ACTG 5142: First-line Antiretroviral Therapy With Efavirenz Plus NRTIs Has Greater Antiretroviral Activity Than Lopinavir/Ritonavir Plus NRTIs Slideset.
First-Line Treatment of HIV Infection With Either NNRTI- or PI-Based Regimens Effective for Long-term Disease Control Slideset on: MacArthur RD, Novak.
HIV Drug Resistance Surveillance Satellite Session: HIV Drug Resistance Surveillance and Control: a Global Concern Silvia Bertagnolio, MD WHO,
EPZICOM ® Virologic Response in ART-Naïve Patients with Baseline Viral Loads Above and Below 100,000c/mL Using the A5202 Endpoint K. Pappa, J. Hernandez,
Switch to PI/r monotherapy
Treatment-Naïve Adults
ARV-trial.com Switch to TDF/FTC/EFV AI Study 1.
Dolutegravir plus Rilpivirine as Maintenance Dual Therapy SWORD-1 and SWORD- 2: Design
XVI International AIDS Conference
Module 4: Role Playing and Case Discussions
Validating Definitions of Antiretroviral Treatment Failure in Malawi
Pharmacokinetics: HIV Drugs
Better Retention Rates Observed in Patients on Lopinavir than Atazanavir in Uganda
HIV Management: An Update on the Latest EACS Guidelines
St Stephen’s Centre, Chelsea & Westminster Hospital, United Kingdom
Long-Term Clinical and Immunologic Outcomes Are Similar in HIV-Infected Persons Randomized to NNRTI versus PI versus NNRTI+PI-based Antiretroviral Regimens.
Switch to DRV/r monotherapy
Switch to LPV/r monotherapy
Comparison of NNRTI vs PI/r
Switch to LPV/r monotherapy
Switch to RAL-containing regimen
Switch to RAL-containing regimen
ARV-trial.com Switch to TDF/FTC/EFV AI Study 1.
Switch to LPV/r monotherapy
ARV-trial.com Switch to FTC + ddI + EFV ALIZE 1.
بسم الله الرحمن الرحيم.
Update on global progress in ART
Presentation transcript:

BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve

audit projects Reporting now:  Survey and case note review of patients switching therapy for the first time  Re-audit of patients starting therapy from naïve – previous audit autumn Reported at spring conference 2005:  Survey of management of HIV/TB co- infection.

Audit of switching therapy 134 centres responded, with data on 504 patients. Of these centres:  100 (75%) rely on BHIVA guidelines on ART  28 (21%) have local guidelines in addition to BHIVA  6 (4%) did not answer.

Management of viral load rebound after previous undetectability Reported practice when switching ART for VL rebound was:  77 (57%) delay until VL > 1000 for resistance test  3 (2%) delay for other reasons.  17 (13%) switch after second VL > 400  11 (8%) switch after second VL > 50  26 (19%) not sure, no answer or no preferred practice.

Cost of ART drugs No respondent said cost was a main or major consideration in the choice of ART drugs:  72 (54%) said they took cost into account  59 (44%) said cost was not a consideration  3 (2%) did not answer.

Case note review of patients switching therapy Data was received on 504 patients. Exclusions:  Switch less than 12 weeks from starting therapy  Second or subsequent switch. 67 patients were excluded as ineligible, leaving 437 for analysis.

Demographic data

Trial participation 18 (4%) of the 437 analysed patients were reported to be in clinical trials related to ART.

Duration on treatment before switch Number of patients

Drug regimens prior to switch

Reasons for switching therapy  223 (51%) toxicity, including 71 (16%) metabolic problems  132 (30%) virological failure  63 (14%) adherence difficulties  43 (10%) patient choice  42 (10%) treatment simplification  21(5%) poor CD4 response NB: more than one reason could be given for each patient.

Reasons for switching therapy (continued)  22 (5%) co-morbidity (3%) +/or potential for drug interactions (3%)  15 (3%) therapy not meeting current recommendations  14 (3%) planning pregnancy  5 (1%) pregnant  3 (<1%) trial end-point. NB: more than one reason could be given for each patient.

Virological failure Virological failure (rebound, not reaching undetectability, and/or increase in VL) was cited as a reason for switching therapy in 132 (30%) of patients.

Time to switch in VL rebound Of the 70 patients who had ever had undetectable VL, the time from the first consistently detectable VL to the change of therapy was:  24 (34%) more than 6 months  14 (20%) 4-6 months  30 (43%) less than 4 months.

Duration on therapy before rebound Duration on therapy before switch of 70 patients who had achieved undetectability before rebound:  10 (14%) less than one year  19 (27%) one to two years  41 (59%) more than two years

Time to switch for patients who did not achieve undetectability Duration on therapy before switch of 62 patients who were not reported to have achieved VL undetectability.

Resistance testing in patients with virological failure Among 132 patients switching for virological failure:  95 (72%) switched after a resistance test result had been obtained  12 (9%) switched while resistance testing was being done but before results were available  4 (3%) had a sample stored for future resistance testing  14 (11%) were neither tested for resistance nor had a sample stored  7 (5%) information was unclear.

Virological failure, cont Of 132 patients with virological failure:  64 (48%) switched to 3 or more new drugs*  42 (32%) switched to 2 new drugs  26 (20%) switched to one new drug 88% of those on an NNRTI regimen switched to a PI. 67 % of patients on a PI regimen remained on a PI and 33% switched to an NNRTI. *RTV at booster dose was not counted. FTC was not counted as a new drug in patients previously taking 3TC.

Conclusions of switch audit Some patients remained on therapy with detectable VL for long periods before switching for virological failure. In over a quarter of patients with reported virological failure a resistance test result was not obtained before switching therapy.

Conclusions of switch audit, cont. Toxicity was the main reason for switching therapy. Few patients were reported to be in clinical trials. Caveat: a substantial number of patients were excluded from analysis, and some of those remaining in the data-set may not have been switching therapy for the first time.

Re-audit of patients starting therapy from naive Key conclusions of 2002 audit:  Significant delays can occur between diagnosis and starting ART even for patients with extremely low CD4.  BP, glucose +/or lipids were not measured before starting ART in a substantial proportion of patients. We re-audited up to 5 patients per centre who started therapy between 1 April and 30 September 2004.

Demographics Of 495 patients submitted for the re-audit:  52% were male and 48% female  50% were Black-African, 34% white, 7% other and 9% unstated. 13 patients were reported to be taking part in clinical trials of ART.

Reasons for starting ART  423 (86%) advanced disease eg low CD4 and/or symptoms  64 (13%) prevention of vertical transmission  6 (1%) recent seroconversion  18 (4%) other reasons. NB: More than one reason could be cited for each patient.

Time from diagnosis to starting ART  299 (60%) within 3 months of diagnosis  55 (11%) 3-6 months after diagnosis  135 (27%) more than 6 months after diagnosis  6 (1%) information missing.

CD4 just before starting treatment Overall, 306 (62%) patients started ART at CD4 <200, including 110 (22%) at <50. Starting ART at low CD4 was associated with recent diagnosis.

Pre-treatment CD4 in patients diagnosed less than 3 months before starting treatment

Pre-treatment CD4 in patients diagnosed more than 6 months before starting treatment

Baseline tests performed Blood pressure Serum lipids Random glucose Liver function Hepatitis B Hepatitis C Proportion of patients reported to have undergone baseline tests:  2002; 2004.

Baseline resistance testing In 2002 only 10% of patients were tested for HIV resistance before starting ART data were:  142 (29%) tested before starting ART  16 (3%) previously tested.  84 (17%) sample stored  228 (46%) resistance test not done  25 (5%) information missing.

Conclusions from audit of starting ART from naïve Patients continue to start ART later than guidelines recommend. This is partly but not solely attributable to late diagnosis. Baseline testing rates have improved since 2002, but key tests were not recorded for a significant minority of patients. The majority of patients did not have a resistance test result before starting ART. The low rate of trial participation in both audits remains unexplained.